PPIB and metabolic dysfunction-associated steatohepatitis: Because of high mortality in other cyclophilin knockout lines subjected to the STZ-WD model, we could not analyze the development of NASH or HCC in those mice and thus we cannot say positively that CypD inhibition is solely responsible for decreasing tumor burden with CRV431 or NV556, which inhibit all cyclophilins.